Papers, explained in our own words

49. Maleimide availability in thiol-maleimide peptide conjugation on PEGylated liposomes: a reactive-site accounting framework illustrated using hepatic drug-delivery systems

Maroof K, Genç R

Peptide-targeted PEGylated liposomes are a widely investigated active-targeting strategy for hepatocellular carcinoma (HCC) and other hepatic indications. A critical but underreported formulation variable is effective maleimide availability: the number of outward-facing, unhydrolysed, sterically accessible maleimide…

• DSPE-PEG-maleimide
• conjugation efficiency
• hepatic nanomedicine
• hepatocellular carcinoma
• maleimide availability
• peptide-targeted liposomes
• thiol-maleimide conjugation

50. Engineered Magnetic Nanoparticles for Dual-Modality Cancer Therapy: Advances in Hyperthermia and Magnetically Controlled Drug Delivery

Murugan S, Ashokkumar M

Cancers remain among the most lethal diseases worldwide, accounting for a substantial proportion of human mortality. Despite significant advances, conventional therapeutic strategies are often limited by tumor microenvironment-mediated resistance, non-specific biodistribution, and severe systemic toxicity…

• cancer treatment
• magnetic hyperthermia
• magnetically triggered drug delivery
• self-regulated heating

51. Bioactivatable conjugated nanocarriers for synergistic mRNA-mediated cancer immunotherapy

Nazir N, Gajjar Tb, Hanumanthayya M, Bainsal N, Singhal D, Smerat A, Et Al.

mRNA immunotherapy holds transformative potential in oncology, yet single-agent approaches frequently fail against immunosuppressive tumor microenvironments (TMEs). Bioactivatable co-delivery of immunogenic chemotherapy alongside mRNA offers mechanistically synergistic advantages, yet coformulation of hydrophobic…

• Immunogenic cell death
• Lipid nanoparticles
• ROS-responsive prodrug
• Tumor microenvironment
• cGAS-STING
• mRNA cancer vaccine

52. Manganese dioxide-entrapping dendrimers as a therapeutic peptide vaccine for combined tumor chemodynamic/immune therapy and tumor prevention

Xia L, Wang J, Li A, Li Y, Liu J, Shi X, Et Al.

Developing a vaccine that can both elicit robust antitumor immune responses and exert potent tumoricidal effects remains a formidable challenge. Herein, we design a functional dendrimer nanocarrier to co-deliver manganese dioxide (MnO 2 ) nanoparticles (NPs) and ovalbumin peptide antigen OVA 257-264 for synergistic…

• Chemodynamic therapy
• Dendrimers
• Immunotherapy
• Manganese dioxide nanoparticles
• Nanovaccine

53. Lipid Nanoparticle-Encapsulated mRNA Encoding CagW, a Conserved Component of the Helicobacter pylori Type IV Secretion System, Protects Mice Against H. pylori Challenge

Zhao Y, Cheng H, Zhou S, He L, Xiu C, Huang B, Et Al.

Background: Roughly one person in two carries Helicobacter pylori, a pathogen classified by the World Health Organization as a group I carcinogen, and the steady loss of antibiotic efficacy has made prophylaxis an urgent rather than an optional goal. No mRNA vaccine against this organism has yet been tested in the…

54. Nisin-Loaded Solid Lipid Nanoparticles (SLN-Nisin) Mitigate Treponema denticola Intracellular Infection and Restore Highly Dysregulated Host Gene Expression

Radaic A, Malone E, Lin S, Curcino Araujo Ld, Tse I, Ganther S, Et Al.

Background/Objectives: Periodontal disease is a bacterially driven chronic inflammatory condition that compromises tooth-supporting tissues. Treponema denticola is strongly associates with periodontal tissue destruction and tooth loss. Given the contribution of antibiotic overuse, the rise of multi-drug resistance…

• SLN-Nisin
• Treponema denticola
• antimicrobial peptides
• nisin
• periodontal disease
• solid lipid nanoparticles

55. Phenotype rescue through the restoration of full-length dystrophin using CRISPR/Cas9 genome editing in Duchenne muscular dystrophy patient-derived iPSCs carrying the deletion of two exons

Rovina D, Milasi S, Di Giuseppe G, Pioner Jm, Langione M, Giammarino L, Et Al.

Duchenne muscular dystrophy (DMD) is a X-linked disease affecting skeletal and cardiac muscle and is caused by mutations in the dystrophin gene (DMD). Patient-derived induced pluripotent stem cells (iPSCs) serve as reliable in vitro disease models. Their genetic correction by CRISPR/Cas9 allows the generation of…

• CRISPR/Cas9
• Duchenne muscular dystrophy
• Dystrophin
• cardiomyocytes, stromal cells, engineered heart tissue
• iPSC

56. Fucoidan-functionalized liposomal nanocarriers for targeted miR-217-5p delivery and combined antitumor treatment in pancreatic ductal adenocarcinoma

Tan C, Fang Y, Guo R, Zheng Z, He M, Yang J, Et Al.

The clinical translation of microRNA (miRNA) therapy is hindered by poor tumor specificity and inefficient delivery. In this study, we constructed a targeted nanoplatform using marine sulfated polysaccharide fucoidan (FU) to encapsulate miR-217-5p in FU-modified cationic liposomes (FU-LIP-miR) for the treatment of…

• CTNNB1
• Fucoidan
• Liposome
• PDAC
• miR-217-5p

57. An mRNA-lipid nanoparticle vaccine against H5N1 influenza virus protects lactating dairy cows from infection

Santos Jjs, Souza Ck, Zanella Gc, Goulart Db, Arruda B, Boggiatto P, Et Al.

Highly pathogenic avian influenza (HPAI) clade 2.3.4.4b H5N1 virus has recently emerged in dairy cattle in the USA, leading to mastitis and sharp reductions in milk production. The main site of H5N1 viral replication is the mammary tissue rather than the respiratory tract and viral transmission between animals is…

58. Oncolytic Virus-like Nanoparticle Targets the Golgi Apparatus via Sphingomyelin

He L, Yang L, Ren M, Wang J, Zhao W, Yang C, Et Al.

The Golgi apparatus (GA) has emerged as a promising target for cancer therapy. Commonly, therapeutics are guided to the GA by recognizing specific receptors on the GA membrane. However, the low and heterogeneous expression of these receptors often results in suboptimal targeting efficiency. Here, we present an…

• Cancer gene therapy
• Golgi apparatus targeting
• Immunogenic cell death
• Nanomedicine
• Pore-forming protein

59. cGAS-mediated immunogenicity impairs the stability and safety of LNP-encapsulated DNA in vivo

Wang X, Liu T, Long B, Li M, Yao Y, Fu Y, Et Al.

DNA-based non-viral gene therapy offers a promising platform for titratable gain-of-function treatments, enabling multi-dosing and sustained efficacy. However, its clinical translation has been constrained by unintended immune activation. We systematically investigated the pathogenesis of DNA drug-induced toxicity in…

• LNP-DNA
• MT: Nucleic Acid Immunity
• MyD88
• TREX1
• cGAS
• gene therapy
• inflammation
• interferon
• plasmid DNA
• toxicity

60. A structure-based virtual screening-driven discovery pharmaceutics platform for cancer therapeutics development: FDA 505(b)(2) repurposing of netupitant as a BMX-targeted nanomedicine using quality-by-design lipid nanoparticles and model-informed PBPK translation

Singirikonda M, Patel T, Parupathi P, Nagarajan A, Patel Js, Devarakonda L, Et Al.

Bone marrow tyrosine kinase on chromosome X (BMX) is an emerging therapeutic target implicated in prostate cancer progression, metastatic disease, and resistance to current therapies; however, no selective BMX-targeted therapy has advanced to clinical development.

• Artificial intelligence
• Bone marrow tyrosine kinase on chromosome X (BMX)
• Cancer therapeutics
• Discovery pharmaceutics
• Drug repurposing
• FDA 505(b)(2)
• Lipid nanoparticles (LNPs)
• Model-informed drug development (MIDD)
• Physiologically based pharmacokinetic (PBPK) modeling

61. In Vivo Blood Kinetics and Transcript Integrity of Three mRNA-Lipid Nanoparticle Vaccines in Humans

Kent Sj, Li S, Amarasena Th, Reynaldi A, Leeming Mg, Juno Ja, Et Al.

mRNA-lipid nanoparticle (LNP) vaccines are detectable in human blood after vaccination, but platform-specific differences in systemic persistence and transcript integrity remain poorly defined. We analyzed serial blood samples from 73 participants receiving Moderna mRNA-1273 (three formulations), Pfizer/BioNTech…

• PEG immunogenicity
• PEGylated lipid nanoparticle
• SARS-CoV-2
• bio−nano interactions
• mRNA degradation
• nanoparticle clearance and biodistribution
• vaccine pharmacokinetics

62. JAG1-siRNA-Lipid Nanoparticles Suppress Infantile Hemangioma Angiogenesis

Teng Y, Xu X, Gao J, Liu J

Background : Infantile hemangioma (IH) is the most common benign vascular tumor of infancy, and propranolol, the current first-line treatment, requires prolonged twice-daily dosing and has adverse systemic effects. Methods : Using the public GSE127487 transcriptomic dataset together with weighted gene coexpression…

• JAG1
• Notch signaling
• angiogenesis
• gene delivery
• infantile hemangioma
• lipid nanoparticle
• siRNA
• targeted nanomedicine

63. Phenolic Hydroxyl-Containing Lipid Nanoparticles Enable Codelivery of HPV Peptide Antigens and Manganese Adjuvant for Cancer Immunotherapy

Hou S, Zhou D, Zhang Y, Li Y, Fan D, Hu Y, Et Al.

Therapeutic peptide vaccines against HPV-associated cancers are often limited by insufficient immunogenicity and inefficient intracellular delivery. Here, we develop a phenolic hydroxyl-containing lipid nanoparticle (EMT@LNP) as a nanomedicine platform for the coordinated codelivery of HPV16 E6/E7 peptide antigens…

• HPV16 E6/E7
• cancer nanovaccine
• lipid nanoparticles
• lymph node delivery
• manganese adjuvant
• tumor immunotherapy

64. Engineered Natural Membrane Vesicle Exosomes as a Torin2 Delivery Platform for Targeted Therapy of Anaplastic Thyroid Carcinoma

Wang C, Zhang X, Qin G, Han P, Li Y, Wang X

Anaplastic thyroid carcinoma (ATC) is a highly aggressive malignancy with poor prognosis due to rapid progression and resistance to conventional therapies. Integrin αvβ3 is overexpressed in ATC, making it a promising target. Torin2, a potent mTOR inhibitor, shows antitumor activity but suffers from poor solubility…

• Torin2
• anaplastic thyroid carcinoma
• exosome
• iRGD peptide
• tumor therapy

65. Advances and Translational Challenges in mRNA–Lipid Nanoparticle Vaccines Against Helicobacter pylori : From Rational Antigen Design to Mucosal Immunity

Zhao Y, Cheng H, Zhou S, He L, Xiu C, Huang B, Et Al.

Helicobacter pylori chronically infects more than half of the global population and is the sole bacterium classified as a Group 1 carcinogen by the International Agency for Research on Cancer. Despite decades of effort, no prophylactic H. pylori vaccine has reached the market, largely because conventional subunit and…

66. Exosome-Inspired Proteolipid Nanoparticles Enable Safe, Extrahepatic RNAi-Chemo Therapy Through Cholesterol-Free, Tumor-Preferential Delivery

Ren Y, Wang Q, Li P, Zhang Z, Wei G, Tan Y, Et Al.

Lipid nanoparticle (LNP)-enabled genetic medicines are reshaping cancer therapy yet remain constrained by liver-biased tropism, dose-limiting toxicities, and limited efficacy in refractory solid tumors such as pancreatic ductal adenocarcinoma (PDAC). Here, exosome-inspired proteolipid nanoparticles (Em-pLNPs) are…

• exosome mimetics
• extrahepatic delivery
• gene therapies
• lipid nanoparticles
• pancreatic ductal adenocarcinoma

67. Comparative Analysis of Poly(Ethylene Glycol) (PEG) and Poly(2-Ethyl-2-Oxazoline) (PEtOx) for Organic Solvent-Free Lipid Nanoparticle Formulations

Streiber M, Holick Ct, Gath L, Tsarenko E, Bachmann V, Litsiou S, Et Al.

Efficient, biocompatible, and flexible application of CRISPR-Cas9 remains a major challenge in gene therapy. This study addresses a novel formulation method, focusing on organic solvent-free lipid nanoparticles for the efficient delivery of CRISPR-Cas9 components. Therefore, novel stealth lipids comprising the lipid…

• CRISPR‐Cas9
• lipid nanoparticles
• liquid chromatography
• mRNA delivery
• organic solvent‐free

68. Lipid Nanoparticle Delivery of CAR276 mRNA Enables Antigen-Specific Cytotoxicity in T Cells Against Glioblastoma Cells

Zahedipour F, Sadeghianfard S, Wisser S, Dinarvand M, Steiner D, Ramesh A, Et Al.

Background/Objectives: Glioblastoma multiforme (GBM) remains the most aggressive and treatment-refractory primary brain tumor, with current therapeutic modalities providing minimal survival improvement. Chimeric antigen receptor (CAR)-based immunotherapies succeeded in hematologic malignancies but are constrained in…

• CAR-T cell engineering
• CD276 (B7-H3)
• glioblastoma
• lipid nanoparticles
• mRNA delivery

69. Biomimetic Nanoparticles With Overexpressed Adhesion Proteins for Targeted Delivery of Gambogic Acid in Hepatocellular Carcinoma

Zhang Y, Yang M, Wu Y, Zhang Y, Xu J, Zheng J, Et Al.

Cancer cell membrane coating offers a promising strategy for targeted drug delivery, yet its homotypic targeting mechanism and optimization remain insufficiently understood. This study identifies epithelial cell adhesion molecule (EpCAM), rather than Galectin-3, as the pivotal mediator of homologous uptake in…

• Biomimetic nanoparticles
• Cell membrane coating
• Clathrin‐mediated endocytosis
• EpCAM overexpression
• Homologous tumor targeting

70. Synthetic Poly(2-Oxazoline) Chimera 'Lipo-Polymers' as Replacements for Key Lipids in Lipid Nanoparticles

Ramsey Jd, Haney M, Zhao Y, Hutsell H, Kabanov A

Lipid nanoparticles (LNPs) rely on specialized lipid components, many of which are proprietary and difficult to access or modify. Here, we introduce a polymer-based alternative to key LNP constituents through the development of chimera poly(2-oxazoline) (POx) synthetic lipid polymers (SLPs) and synthetic lipid…

71. Self-Catalyzed Transesterification Transforms Ionizable Amphiphilic Janus Dendrimers into Multicomponent Vectors and Generates Complex Design Strategies for mRNA Delivery

Lu J, Atochina-Vasserman En, Sahoo D, Maurya Ds, Tiwary A, Arshad M, Et Al.

Genetic nanomedicine delivers nucleic acids by viral and synthetic vectors to produce drugs directly in the body's own cells. Each approach presents relative advantages, but synthetic vectors are distinguished by their effectively unlimited synthetic capabilities. The leading synthetic vectors are the four-component…

72. Uncovering the lymphatic uptake, pharmacokinetics, and biodistribution of mRNA-lipid nanoparticles after intravenous and subcutaneous injection

Li P, Abdallah M, Yao Y, Mugan Rs, Payne Tj, Fabb Sa, Et Al.

Lipid nanoparticle (LNP) formulations have enabled the in vivo delivery of messenger ribonucleic acid (mRNA) vaccines and therapeutics yet the delivery of RNA remains relatively inefficient. In order to improve LNP design there is a need to better understand how current mRNA-LNP formulations are trafficked and…

• Biodistribution
• Intravenous injection
• Ionizable lipid
• Lipid nanoparticle
• Lymphatics
• Pharmacokinetics
• Subcutaneous injection
• mRNA